Form 8-K - Current report:
SEC Accession No. 0001437749-25-034635
Filing Date
2025-11-13
Accepted
2025-11-13 08:36:12
Documents
15
Period of Report
2025-11-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20251112_8k.htm   iXBRL 8-K 26347
2 EXHIBIT 99.1 ex_887936.htm EX-99.1 15675
7 logobig.jpg GRAPHIC 19220
  Complete submission text file 0001437749-25-034635.txt   234229

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20251113.xsd EX-101.SCH 3581
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20251113_def.xml EX-101.DEF 11809
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20251113_lab.xml EX-101.LAB 15860
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20251113_pre.xml EX-101.PRE 12024
17 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20251112_8k_htm.xml XML 2946
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 251475611
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)